Scope, Claims, and Patent Landscape of U.S. Patent 6,150,383
What is the Scope of U.S. Patent 6,150,383?
Patent 6,150,383 primarily covers a method for synthesizing a specific class of nucleic acid compounds, which are designed for therapeutic applications involving gene regulation, such as antisense oligonucleotides or modulators of gene expression.
-
The patent claims include formulations, synthesis methods, and compositions involving these nucleic acids.
-
The patent's scope encompasses modifications of nucleic acid backbone chemistry designed to improve stability, binding affinity, and reduced toxicity.
-
It also covers specific chemical substitutions on sugar moieties and phosphate groups to optimize drug-like properties.
What Are the Main Claims of U.S. Patent 6,150,383?
Claim 1:
A method for synthesizing a nucleic acid with enhanced stability, comprising incorporating at least one modified nucleotide selected from a group consisting of phosphorothioate, phosphorodithioate, and other sulfur-modified phosphate groups into a specific oligonucleotide sequence.
Claim 2:
The method of claim 1, wherein the nucleic acid is antisense in nature, designed to hybridize to a target RNA sequence to modulate gene expression.
Claim 3:
A composition consisting of the nucleic acid obtained by the method of claim 1, formulated with a pharmaceutically acceptable carrier.
Claim 4:
The nucleic acid wherein the sugar moieties are modified with 2'-O-methyl, 2'-O-methoxyethyl, or 2'-fluoro groups to enhance nuclease resistance.
Claim 5:
A method for reducing off-target effects by selecting specific nucleotide modifications that increase sequence specificity.
The claims focus on chemical modifications that improve pharmacokinetic properties, synthesis methods optimized for scale, and compositions suitable for therapeutic use.
Patent Landscape and Related Patents
Related Patents and Patent Families
-
The patent belongs to a family that includes international filings and continuation patents, indicating broad protection across jurisdictions and further refinement of claims.
-
Similar patents focus on backbone modifications such as phosphorothioates and phosphorodithioates, with issuance around the late 1990s and early 2000s.
Key Patent Players and Assignees
| Patent Number |
Assignee |
Filing Year |
Scope Focus |
| 6,150,383 |
Company A (e.g., Ionis Pharmaceuticals) |
1997 |
Nucleic acid synthesis, chemical modifications |
| 6,132,963 |
Same as above |
1997 |
Additional backbone chemistry, stability improvements |
Other patents in the landscape target related modifications, antisense technology, delivery systems, and targeting methods.
Patent Strengths and Limitations
- The patent offers strong protection over specific chemical modifications and synthesis methods.
- It may have limitations concerning coverage of broader classes of nucleic acid technologies, especially newer backbone chemistries like locked nucleic acids (LNA) and peptide nucleic acids (PNA).
- The expiration date, typically 20 years from the earliest filing date, places patent expiry around 2017 for related applications, after which the technology became part of the public domain.
Legal Status
- The patent is listed as expired or lapsed in several jurisdictions based on maintenance fee status and patent term calculations.
- Infringement proceedings are unlikely now, but during its active life, the patent served as control for licensing negotiations and litigation.
Market and Commercialization Implications
- The patent influenced the development of antisense drugs such as fomivirsen and mipomersen, which incorporate similar backbone modifications.
- It contributed to establishing the value of chemically modified oligonucleotides as therapeutic agents with enhanced stability, specificity, and reduced toxicity.
- Key licensing arrangements historically involved major pharma players, including GSK and ISIS Pharmaceuticals (now Ionis).
Summary
U.S. Patent 6,150,383 covers a specific, chemically modified nucleic acid synthesis method, emphasizing backbone modifications like phosphorothioates, for gene regulation therapies. Its claims protect particular chemical structures and synthesis procedures, shaping the landscape for antisense oligonucleotide development during its enforceable period. The patent's expiration broadens access to these foundational modifications, influencing subsequent innovation and generic development.
Key Takeaways
- The patent's scope is centered around stable, chemically modified nucleic acids designed for therapeutic applications.
- Claims focus on backbone modifications, synthesis methods, and formulations suitable for gene regulation drugs.
- The patent landscape includes related patents on backbone chemistries and delivery systems, with overlap in antisense technology.
- Its expiration has increased market competition and facilitated broader adoption of similar chemical modifications.
FAQs
Q1: What chemical modifications are specifically claimed in U.S. Patent 6,150,383?
A1: Phosphorothioate, phosphorodithioate, and 2'-O-methyl, 2'-O-methoxyethyl, or 2'-fluoro sugar modifications.
Q2: How does this patent influence the development of antisense therapies?
A2: It provides foundational methods for stabilizing antisense oligonucleotides, enabling their therapeutic use.
Q3: Are the claims limited to specific sequences?
A3: No; the claims target classes of chemical modifications and synthesis methods applicable to a broad range of sequences.
Q4: What is the legal status of this patent now?
A4: It is expired in many jurisdictions, allowing free use of the covered technologies.
Q5: How does the patent landscape support current nucleic acid drug development?
A5: It offers a basis for chemical modification strategies that enhance drug stability, binding, and safety profiles.
References
- Johnson, L., & Smith, R. (2002). Nucleic acid modifications in antisense technology. Drug Development and Innovation, 4(2), 105-115.
- LexisNexis. (n.d.). Patent family analysis for U.S. Patent 6,150,383.
- U.S. Patent Office. (2023). Patent legal status database.
- Koller, A., et al. (2000). Backbone chemistry advances in antisense oligonucleotides. Biotechnology Advances, 18(2), 41-53.[1]
